MAPK1 and breast carcinoma: Like flavonols, flavan-3-ols (50 μM) are found to have a potential use in cancer treatment considering that they can inhibit FAK and significantly lower the levels of phospho-ERK (20 μM), as demonstrated in pancreatic cancer, breast cancer, melanoma and fibrosarcoma cells [153,154].